Personalis, Inc.
PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tiā¦ read more
Healthcare
Diagnostics & Research
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.66
Price+3.10%
$0.38
1Y
Price
Market Cap
$1.351b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-132.3%
EBITDA Margin-149.4%
Net Profit Margin-161.6%
Free Cash Flow Margin-132.3%
EBITDA Margin-149.4%
Net Profit Margin-161.6%
Free Cash Flow MarginRevenue
$64.515m
-18.3%
1y CAGR+3.3%
3y CAGR-3.5%
5y CAGREarnings
-$95.552m
+9.1%
1y CAGR+12.8%
3y CAGR-8.8%
5y CAGREPS
-$1.02
+35.8%
1y CAGR+28.1%
3y CAGR+4.4%
5y CAGRBook Value
$254.765m
$325.395m
Assets$70.630m
Liabilities$38.781m
DebtDebt to Assets
11.9%
-0.7x
Debt to EBITDAFree Cash Flow
-$84.648m
-41.5%
1y CAGR+11.0%
3y CAGR-3.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company